The guidance reduction reflects continued weakness in US Hips and Knees, which the company expects to persist through Q4. Watch for any further strategic action on Orthopaedics (spin-off, sale, or partnership) and for Q4 results on March 1, 2027 to see if the lowered guidance is achieved.
Price Chart
Executive Summary
Smith+Nephew reported Q3 2026 revenue of $1,551M (+3.4% YoY), in line with the $1.56B consensus. Full-year guidance was lowered: underlying revenue growth cut to ~3% (from ~4%), trading profit growth to ~4% (from ~8%), and free cash flow to ~$750M (from ~$800M). The company disclosed that exploratory deal discussions with Johnson & Johnson regarding its Orthopaedics business have ended, but it continues to review strategic options for the unit.
Key Financial Metrics
Key Facts
- Q3 revenue $1,551M vs $1,501M a year ago, +3.4% underlying and reported growth
- Full-year underlying revenue growth guidance lowered to ~3% from ~4%
- Full-year trading profit growth guidance lowered to ~4% from ~8%; trading profit now ~$1.25B vs prior ~$1.3B
- Free cash flow guidance lowered to ~$750M from ~$800M
- Adjusted ROIC guidance lowered to ~9% from >10%
- US Knee Implants revenue declined -7.3% YoY; US Hip Implants declined -1.0%
- Exploratory discussions with Johnson & Johnson regarding Orthopaedics business have ended
- Board continues to explore full range of strategic options for Orthopaedics
- Share buyback of $500M on track with $250M completed by end of Q3
Financial Impact
Revenue guidance cut by ~1pp (from ~4% to ~3% underlying); trading profit guidance cut by ~$50M (from ~$1.3B to ~$1.25B); free cash flow guidance cut by ~$50M (from ~$800M to ~$750M)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Sports Medicine & ENT | $507.0M | +7.9% |
| Advanced Wound Management | $454.0M | -0.2% |
| Orthopaedics | $590.0M | +2.5% |
Risk Factors
- US Orthopaedics market softness may persist longer than expected
- Advanced Wound Bioactives revenue continues to decline (-8.8% underlying) due to reimbursement changes
- Failure to find a strategic buyer or partner for Orthopaedics could lead to continued underperformance
- China VBP headwinds remain a risk for Arthroscopic Enabling Technologies and ENT segments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-009493 |
| Document: 0001654954-26-009493-index-headers.html | 0001654954-26-009493 |
| Document: 0001654954-26-009493-index.html | 0001654954-26-009493 |
| Document: 0001654954-26-009493.txt | 0001654954-26-009493 |
| Earnings Context (Synthetic; results releases only) | 0001654954-26-009493 |
Track record
42 reports on SNN
6 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
- Nov 4, 202612d ago 6-K Bearish 6/10 Viewing No price data
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
- Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
- Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
- Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers